Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D03ESO
|
|||
Former ID |
DPR000055
|
|||
Drug Name |
GW-3333
|
|||
Synonyms |
SMZPWUUYPYYHIV-HNJRGHQBSA-N; GW3333; CHEMBL514958; UNII-54J77T5T74; 54J77T5T74; 212609-68-2; AC1Q5NWC; AC1L50QR; BIDD:PXR0031; n2-[(2r,3s)-3-[formyl(hydroxy)amino]-4-methyl-2-(2-methylpropyl)pentanoyl]-n-pyridin-2-yl-l-isoleucinamide; SCHEMBL2875070; BDBM50247805; (2R,3S)-3-[formyl(hydroxy)amino]-4-methyl-N-[(2S,3S)-3-methyl-1-oxo-1-(pyridin-2-ylamino)pentan-2-yl]-2-(2-methylpropyl)pentanamide; (2R,3S)-3-(Formyl-hydroxyamino)-2-(2-methyl-1-propyl)-4-methylpentanoic acid, ((1S,2S)-2-methyl-1-(2-pyridylcarbamoyl)-1-butyl)amide; GW3333; Gw 3333; N2-[(2r,3s)-3-[formyl(hydroxy)amino]-4-methyl-2-(2-methylpropyl)pentanoyl]-n-pyridin-2-yl-l-isoleucinamide; 5-carboxymethylthio-3-(3'-chlorophenyl)-1,2,4-oxadiazol
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J44, J44.9] | Preclinical | [1] | |
Company |
GlaxoSmithKline
|
|||
Structure |
Download2D MOL |
|||
Formula |
C22H36N4O4
|
|||
Canonical SMILES |
CCC(C)C(C(=O)NC1=CC=CC=N1)NC(=O)C(CC(C)C)C(C(C)C)N(C=O)O
|
|||
InChI |
1S/C22H36N4O4/c1-7-16(6)19(22(29)24-18-10-8-9-11-23-18)25-21(28)17(12-14(2)3)20(15(4)5)26(30)13-27/h8-11,13-17,19-20,30H,7,12H2,1-6H3,(H,25,28)(H,23,24,29)/t16-,17+,19-,20-/m0/s1
|
|||
InChIKey |
SMZPWUUYPYYHIV-HNJRGHQBSA-N
|
|||
CAS Number |
CAS 212609-68-2
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
References | Top | |||
---|---|---|---|---|
REF 1 | Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. | |||
REF 2 | Crystal structures of cystathionine gamma-synthase inhibitor complexes rationalize the increased affinity of a novel inhibitor. J Mol Biol. 2001 Aug 24;311(4):789-801. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.